Zacks.com on MSN1d
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...
BioSpace4d
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...
FierceBiotech12d
CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager
CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...
Amgen, Wake Tech program to help bolster booming biotech jobs
A dozen students signed letters of intent on Monday to work with Amgen.